公开(公告)号：US11130751B2

公开(公告)日：2021-09-28

申请号：US16499421

申请日：2018-03-29

Applicant: JANSSEN PHARMACEUTICA NV

Inventor： Patrick René Angibaud ,  Olivier Alexis Georges Querolle ,  Didier Jean-Claude Berthelot ,  Christophe Meyer ,  Matthieu Philippe Victor Willot ,  Lieven Meerpoel ,  Thierry François Alain Jean Jousseaume

IPC: C07D413/14 ,  C07D495/10 ,  A61P35/00

Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

公开(公告)号：US10745409B2

公开(公告)日：2020-08-18

申请号：US16469174

申请日：2017-12-14

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick René Angibaud ,  Vineet Pande ,  Barbara Herkert ,  Daniel Jason Krosky ,  Olivier Alexis Georges Querolle ,  Aaron Nathaniel Patrick ,  Isabelle Noëlle Constance Pilatte

IPC: A61K31/381 ,  A61K31/519 ,  A61K31/55 ,  A61P35/00 ,  A61P35/02 ,  C07D495/04

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.